open access

Vol 1, No 2 (2004)
Research paper
Published online: 2004-06-16
Get Citation

What can be measured with neurocognitive tests in schizophrenia?

Anna Mosiołek, Bartosz Łoza
Psychiatria 2004;1(2):113-119.

open access

Vol 1, No 2 (2004)
Prace oryginalne - nadesłane
Published online: 2004-06-16

Abstract

Background. Beyond the dispute over neurodevelopmental or neurodegenerative origins of schizophrenia, patients consistently show performance disturbances on neurocognitive tests. However, the relationship between the clinically rated symptoms or factors and performance-based cognitive test scores has not been sufficiently examined. A major research goal of this study was to validate hypothetical links between clinical and neurocognitive domains.
Material and methods. 136 schizophrenic patients (ICD-10 criteria for paranoid type) were assessed with several neurocognitive tests related to mostly executive functioning and working memory CNS activities (WCST, Stroop, RAVLT, RCFT, TMT-A, TMT-B, Wechsler-digits and verbal fluency). All patients were newly admitted and treated with both typical and atypical antipsychotics. The mean daily chlorpromazine equivalent medication level was 466.6 mg. Principal component analysis (PCA) of PANSS results with varimax normalized rotation was performed and the combination of scree plot inspection and eigenvalues exceeding 1.0 were applied for the factor extraction.
Results. Despite the application of the battery of 34 neurocognitive measurements, only mild to moderate correlations with PANSS variables (totals, subscales and after dimensional transformation) were identified. Among dimensions of extracted factor model, consisting of 5 dimensions (negative, positive, depressive, cognitive and disorganized), only the PANSS cognitive factor was moderately correlated in some aspects with neurocognitive scores.
Conclusion. The PANSS cognitive factor was identified as the most specific to the results of neurocognitive performance. However, only modestly correlated clinical ratings of PANSS with neurocognitive scores suggest that these findings should not be conceptualized as a measurement of the common neurobiological abnormality underlying clinical symptomatology.

Abstract

Background. Beyond the dispute over neurodevelopmental or neurodegenerative origins of schizophrenia, patients consistently show performance disturbances on neurocognitive tests. However, the relationship between the clinically rated symptoms or factors and performance-based cognitive test scores has not been sufficiently examined. A major research goal of this study was to validate hypothetical links between clinical and neurocognitive domains.
Material and methods. 136 schizophrenic patients (ICD-10 criteria for paranoid type) were assessed with several neurocognitive tests related to mostly executive functioning and working memory CNS activities (WCST, Stroop, RAVLT, RCFT, TMT-A, TMT-B, Wechsler-digits and verbal fluency). All patients were newly admitted and treated with both typical and atypical antipsychotics. The mean daily chlorpromazine equivalent medication level was 466.6 mg. Principal component analysis (PCA) of PANSS results with varimax normalized rotation was performed and the combination of scree plot inspection and eigenvalues exceeding 1.0 were applied for the factor extraction.
Results. Despite the application of the battery of 34 neurocognitive measurements, only mild to moderate correlations with PANSS variables (totals, subscales and after dimensional transformation) were identified. Among dimensions of extracted factor model, consisting of 5 dimensions (negative, positive, depressive, cognitive and disorganized), only the PANSS cognitive factor was moderately correlated in some aspects with neurocognitive scores.
Conclusion. The PANSS cognitive factor was identified as the most specific to the results of neurocognitive performance. However, only modestly correlated clinical ratings of PANSS with neurocognitive scores suggest that these findings should not be conceptualized as a measurement of the common neurobiological abnormality underlying clinical symptomatology.
Get Citation

Keywords

schizophrenia; neurocognitive tests; cognitive dimension; PANSS; WCST

About this article
Title

What can be measured with neurocognitive tests in schizophrenia?

Journal

Psychiatria (Psychiatry)

Issue

Vol 1, No 2 (2004)

Article type

Research paper

Pages

113-119

Published online

2004-06-16

Bibliographic record

Psychiatria 2004;1(2):113-119.

Keywords

schizophrenia
neurocognitive tests
cognitive dimension
PANSS
WCST

Authors

Anna Mosiołek
Bartosz Łoza

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl